A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma
British Journal of Haematology | September 25, 2015 | Volume: 174 | Issue: 2 | Pages: 323-325
10.1111/bjh.13765
| PMID 26403323